Eli Lilly has agreed to acquire biopharmaceutical company Morphic Holding for $3.2 billion. The deal strengthens Eli Lilly’s immunology pipeline. Eli Lilly will pay $57 per share for Morphic, representing a 79% premium to the company’s closing price on Friday.
